Recent resignation of FDA Commissioner Marty Makary prompted President Trump to name Kyle Diamantas, the agency's deputy commissioner for food, as acting head in mid-May 2026. Diamantas's immediate elevation and public endorsement from the president have positioned him as the clear frontrunner in trader assessments, reflected in his near-50% implied probability. Administration officials have signaled an active search for a permanent nominee, with early candidates including former commissioner Stephen Hahn and former assistant health secretary Brett Giroir under consideration. Any permanent selection requires Senate confirmation, adding procedural steps that could extend the timeline. Traders appear to weigh Diamantas's current operational role and internal support most heavily in pricing outcomes ahead of a formal announcement.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiKyle Diamantas 43%
Stephen Hahn 7%
Brett Giroir 4.0%
Sara Brenner 3.3%
BARU
BARU
Dec 31, 2026
Kyle Diamantas
47%
Stephen Hahn
7%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
1%
Kyle Diamantas 43%
Stephen Hahn 7%
Brett Giroir 4.0%
Sara Brenner 3.3%
BARU
BARU
Dec 31, 2026
Kyle Diamantas
$1,298 Vol.
47%
Stephen Hahn
$975 Vol.
7%
Brett Giroir
$1,510 Vol.
4%
Grace Graham
$1,842 Vol.
3%
Sara Brenner
$848 Vol.
3%
No announcement by December 31
$425 Vol.
1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary prompted President Trump to name Kyle Diamantas, the agency's deputy commissioner for food, as acting head in mid-May 2026. Diamantas's immediate elevation and public endorsement from the president have positioned him as the clear frontrunner in trader assessments, reflected in his near-50% implied probability. Administration officials have signaled an active search for a permanent nominee, with early candidates including former commissioner Stephen Hahn and former assistant health secretary Brett Giroir under consideration. Any permanent selection requires Senate confirmation, adding procedural steps that could extend the timeline. Traders appear to weigh Diamantas's current operational role and internal support most heavily in pricing outcomes ahead of a formal announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Pasar Dibuka: May 12, 2026, 7:59 PM ET
Volume
$6,898Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary prompted President Trump to name Kyle Diamantas, the agency's deputy commissioner for food, as acting head in mid-May 2026. Diamantas's immediate elevation and public endorsement from the president have positioned him as the clear frontrunner in trader assessments, reflected in his near-50% implied probability. Administration officials have signaled an active search for a permanent nominee, with early candidates including former commissioner Stephen Hahn and former assistant health secretary Brett Giroir under consideration. Any permanent selection requires Senate confirmation, adding procedural steps that could extend the timeline. Traders appear to weigh Diamantas's current operational role and internal support most heavily in pricing outcomes ahead of a formal announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$6,898Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent resignation of FDA Commissioner Marty Makary prompted President Trump to name Kyle Diamantas, the agency's deputy commissioner for food, as acting head in mid-May 2026. Diamantas's immediate elevation and public endorsement from the president have positioned him as the clear frontrunner in trader assessments, reflected in his near-50% implied probability. Administration officials have signaled an active search for a permanent nominee, with early candidates including former commissioner Stephen Hahn and former assistant health secretary Brett Giroir under consideration. Any permanent selection requires Senate confirmation, adding procedural steps that could extend the timeline. Traders appear to weigh Diamantas's current operational role and internal support most heavily in pricing outcomes ahead of a formal announcement.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan